Clinical Trials Logo

Clinical Trial Summary

Administration of the incretin hormone, Glucagon-Like-Peptide-1 (GLP-1), has been shown to enhance insulin secretion and suppress glucagon secretion in response to meal ingestion. In addition, GLP-1 also delays gastric emptying and has been shown to enhance gastric accommodation. These characteristics make GLP-1 an ideal therapy for type 2 diabetes (T2D). However, because of its rapid breakdown by dipeptidylpeptidase IV (DPP IV), GLP-1 has to be administered by continuous intravenous infusion. This would be a drawback in clinical usage. LAF237 is a synthetic inhibitor of DPP IV which has been shown to raise GLP-1 levels and potentiate meal-induced insulin secretion and glucagon suppression. However, the effects of LAF237 on gastric emptying and satiety are at present unknown. The investigators propose to study the effects of LAF237 on gastric emptying, gastric volume and satiety in patients with T2D in addition to examining the direct and indirect (mediated via insulin and glucagon) of this compound on postprandial glucose metabolism.


Clinical Trial Description

n/a


Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT00952991
Study type Interventional
Source Mayo Clinic
Contact
Status Completed
Phase Phase 3
Start date May 2005
Completion date February 2006

See also
  Status Clinical Trial Phase
Completed NCT02801448 - Clinical Trial With Broccoli Sprout Extract to Patients With Type 2 Diabetes Phase 2
Withdrawn NCT01377961 - Effect of Lycopene and Isoflavones on Glucose Metabolism N/A
Completed NCT00754130 - MK-0941 Multiple Dose Study in Japanese Patients With Type 2 Diabetes (MK-0941-011). Phase 1
Completed NCT00006305 - Bypass Angioplasty Revascularization Investigation in Type 2 Diabetes Phase 3
Completed NCT00004983 - Education and Group Support for Diabetic Hispanics N/A
Completed NCT00010751 - Effects of Reiki on Painful Neuropathy and Cardiovascular Risk Factors Phase 2
Completed NCT02299388 - To Evaluate the Effect of Liraglutide on Ambulatory Blood Pressure-A Pilot Study Phase 4
Completed NCT00550329 - Bioequivalence Study Of Glucotrol XL 2.5 Mg Tablets Phase 1
Completed NCT00172536 - Effects of Exercise Training on Left Ventricular Function in Type 2 Diabetic Patients Post Coronary Artery Bypass Graft N/A
Completed NCT00071422 - Safety and Efficacy of INGAP-Peptide in Patients With Type 2 Diabetes Phase 2
Completed NCT00029848 - Obese Patients With Type 2 Diabetes Phase 3
Completed NCT01608724 - The Efficacy and Safety Study in Patients With Type 2 Diabetes Mellitus Phase 4
Completed NCT01694758 - OPtimal Type 2 dIabetes Management Including Benchmarking and Standard Treatment in CEEMEA N/A
Completed NCT00979368 - Safety Study of BMS-816336 in Healthy Male Subjects Phase 1
Completed NCT00791661 - MK-1006 Single Dose Study in Japanese Type 2 Diabetes Patients (MK-1006-005) Phase 1
Active, not recruiting NCT02088658 - Technology Intensified Diabetes Education Study in African Americans N/A
Completed NCT01105429 - Single Ascending Dose Study of BMS-820132 in Patients With Type 2 Diabetes Phase 1
Completed NCT00701090 - A Study to Test the Safety and Efficacy of Sitagliptin Compared to Glimepiride in Patients With Type 2 Diabetes on a Stable Dose of Metformin (0431-803)(COMPLETED) Phase 3
Completed NCT00035984 - Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes Mellitus Phase 3
Completed NCT00044447 - Evaluate the Role of Adding Amaryl to Non-Insulin Dependent Diabetes Mellitus Patients Unresponsive to Maximum Dose Metformin & Thiazolidinedione Phase 3